Biotech | December 14, 2021
Samsung Biologics expands tie-up with AstraZeneca to include cancer therapy
The company will manufacture a cancer immunotherapy product from 2022
The company will manufacture a cancer immunotherapy product from 2022
Ichnos will receive an upfront payment of Euro 20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales
It is a novel oral NLRP3 inflammasome inhibitor
The company is focused on the development of novel treatments for RNA viruses
Investment in single-use endoscopes, digital solutions, and endoluminal therapies expected
_256_384.jpg)
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
The event was organized jointly by Oncology Forum and Fortis Cancer Institute, Delhi NCR
It works with Pfizer to support more rapid innovation and improved clinical manufacturing operations to help develop tomorrow’s therapies
Expanded EUA includes both treatment of patients with Covid-19 and post-exposure prophylaxis (PEP) in high-risk pediatric and infant patients
This further adds to Biocon’s portfolio of vertically integrated complex drug products
Subscribe To Our Newsletter & Stay Updated
